{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:19:53Z","timestamp":1791839993873,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The association between systemic scleroderma and malignancy is well-documented, but there is limited data on the relationship between morphea and malignancy. This study aims to assess the incidence and types of malignancies in morphea patients, comparing demographics, clinical characteristics, treatments, and outcomes between those with and without malignancy. We conducted a retrospective study of 204 morphea patients treated at Rabin Medical Center between 2012 and 2023. Data on demographics, clinical subtypes, comorbidities, treatments, and outcomes were collected. Patients were categorized based on malignancy status and the timing of malignancy relative to their morphea diagnosis. Among the 204 patients (154 women and 50 men, mean age 53.7\u2009\u00b1\u200920 years), 47 (23%) developed malignancies. In 29 patients (61.7%), malignancy occurred before the onset of morphea; in 23 patients (48.9%), it occurred after morphea. Five patients (10.6%) had malignancies both before and after the diagnosis of morphea. Patients with malignancy were significantly older than those without (64.7\u2009\u00b1\u200915.1 years vs. 50.3\u2009\u00b1\u200920 years, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). The all-cause mortality rate was higher in the malignancy group compared to those without malignancy (23.4% vs. 3.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.00002). Moreover, mortality was higher in patients whose malignancy occurred after morphea than in those whose malignancy preceded morphea (26% vs. 17.2%). The most common post-morphea malignancies in our cohort included non-melanoma skin cancer, cervical cancer, breast cancer, stomach cancer, and lung cancer. The most common pre-morphea malignancies included breast cancer, non-melanoma skin cancer, colon cancer, prostate cancer, and testicular cancer. This study suggests potential associations between morphea and malignancies, influenced by patient age, sequence of diagnosis, and treatment regimens. Further control studies are needed to explore these relationships more definitively.<\/jats:p>","DOI":"10.1007\/s00403-024-03357-7","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T14:03:20Z","timestamp":1726063400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring the relationship between morphea and malignancy: a decade-long single-center study of 204 patients"],"prefix":"10.1007","volume":"316","author":[{"given":"Keren","family":"Lyakhovitsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mimouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9433-2636","authenticated-orcid":false,"given":"Anna","family":"Aronovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"3357_CR1","doi-asserted-by":"crossref","unstructured":"Papara C, De Luca DA, Bieber K, Vorobyev A, Ludwig RJ (2023) Morphea: the 2023 update. Front Med ;10","DOI":"10.3389\/fmed.2023.1108623"},{"key":"3357_CR2","doi-asserted-by":"crossref","unstructured":"Szcz\u0229ch J, Samotij D, Jaworecka K, Tobiasz A, Reich A (2020) Quality of Life in Patients with Morphea: A Cross-Sectional Study and a Review of the Current Literature. Biomed Res Int ;2020","DOI":"10.1155\/2020\/9186274"},{"key":"3357_CR3","doi-asserted-by":"crossref","unstructured":"Careta MF, Romiti R (2015) Localized scleroderma: clinical spectrum and therapeutic update. Bras Dermatol ;90","DOI":"10.1590\/abd1806-4841.20152890"},{"key":"3357_CR4","doi-asserted-by":"crossref","unstructured":"Abbas L, Joseph A, Kunzler E, Jacobe HT (2021) Morphea: progress to date and the road ahead. Ann Transl Med ;9","DOI":"10.21037\/atm-20-6222"},{"key":"3357_CR5","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Salgado P, Garc\u00eda-Romero MT (2019) Morphea: a practical review of its diagnosis, classification and treatment. Gac Med Mex ;155","DOI":"10.24875\/GMM.M20000336"},{"key":"3357_CR6","doi-asserted-by":"crossref","unstructured":"Wenzel D, Haddadi NS, Afshari K, Richmond JM, Rashighi M (2021) Upcoming treatments for morphea. Immun Inflamm Dis ;9","DOI":"10.1002\/iid3.475"},{"key":"3357_CR7","doi-asserted-by":"crossref","unstructured":"Szczepanik-Ku\u0142ak P, Michalska-Jakubus M, Krasowska D (2021) Laser therapy for the treatment of morphea: a systematic review of literature. J Clin Med ;10","DOI":"10.3390\/jcm10153409"},{"key":"3357_CR8","doi-asserted-by":"crossref","unstructured":"Lepri G, Catalano M, Bellando-Randone S et al (2022) Systemic Sclerosis Association with Malignancy. Clin Rev Allergy Immunol ;63","DOI":"10.1007\/s12016-022-08930-4"},{"key":"3357_CR9","doi-asserted-by":"crossref","unstructured":"Joly-Chevrier M, G\u00e9linas A, Ghazal S et al (2023) Morphea, Eosinophilic Fasciitis and Cancer: A Scoping Review. Cancers ;15","DOI":"10.3390\/cancers15184450"},{"key":"3357_CR10","doi-asserted-by":"crossref","unstructured":"Heck J, Olk J, Kneitz H, Hamm H, Goebeler M (2020) Long-standing morphea and the risk of squamous cell carcinoma of the skin. JDDG - J German Soc Dermatology ;18","DOI":"10.1111\/ddg.14096"},{"key":"3357_CR11","doi-asserted-by":"crossref","unstructured":"Boozalis E, Shah AA, Wigley F, Kang S, Kwatra SG (2019) Morphea and systemic sclerosis are associated with an increased risk for melanoma and nonmelanoma skin cancer. J Am Acad Dermatol ;80","DOI":"10.1016\/j.jaad.2018.10.022"},{"key":"3357_CR12","doi-asserted-by":"crossref","unstructured":"Lagac\u00e9 F, D\u2019Aguanno K, Prosty C et al (2023) The role of sex and gender in Dermatology - from pathogenesis to clinical implications. J Cutan Med Surg ;27","DOI":"10.1177\/12034754231177582"},{"key":"3357_CR13","doi-asserted-by":"crossref","unstructured":"Li X, Li C, Zhang W, Wang Y, Qian P, Huang H (2023) Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct Target Therapy ;8","DOI":"10.1038\/s41392-023-01502-8"},{"key":"3357_CR14","doi-asserted-by":"crossref","unstructured":"Lian J, Yue Y, Yu W, Zhang Y (2020) Immunosenescence: a key player in cancer development. J Hematol Oncol ;13","DOI":"10.1186\/s13045-020-00986-z"},{"key":"3357_CR15","doi-asserted-by":"crossref","unstructured":"Johnson W, Jacobe H (2012) Morphea in adults and children cohort II: patients with morphea experience delay in diagnosis and large variation in treatment. J Am Acad Dermatol ;67","DOI":"10.1016\/j.jaad.2012.01.011"},{"key":"3357_CR16","doi-asserted-by":"crossref","unstructured":"Hemminki K, Liu X, Ji J, F\u00f6rsti A, Sundquist J, Sundquist K (2012) Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol ;127","DOI":"10.1016\/j.ygyno.2012.07.100"},{"key":"3357_CR17","doi-asserted-by":"crossref","unstructured":"Ardern-Jones MR, Black MM (2003) Widespread morphoea following radiotherapy for carcinoma of the breast. Clin Exp Dermatol ;28","DOI":"10.1046\/j.1365-2230.2003.01186.x"},{"key":"3357_CR18","doi-asserted-by":"crossref","unstructured":"Davis DA, Cohen PR, McNeese MD, Duvic M (1996) Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: Radiation port scleroderma. J Am Acad Dermatol ;35","DOI":"10.1016\/S0190-9622(96)90116-4"},{"key":"3357_CR19","doi-asserted-by":"crossref","unstructured":"Bleasel NR, Stapleton KM, Commens C, Ahern VA (1999) Radiation-induced localized scleroderma in breast cancer patients. Australas J Dermatol ;40","DOI":"10.1046\/j.1440-0960.1999.00330.x"},{"key":"3357_CR20","doi-asserted-by":"crossref","unstructured":"Partl R, Regitnig P, Lukasiak K, Winkler P, Kapp KS (2020) Incidence of Morphea following adjuvant irradiation of the breast in 2,268 patients. Breast Care ;15","DOI":"10.1159\/000502030"},{"key":"3357_CR21","doi-asserted-by":"crossref","unstructured":"Desmond BL, Blattner CM, Young J (2016) Generalized morphea as the first sign of breast carcinoma: a case report. Dermatol Online J ;22","DOI":"10.5070\/D3222030094"},{"key":"3357_CR22","doi-asserted-by":"crossref","unstructured":"Ravic-Nikolic A, Djurdjevic P, Mitrovic S, Milicic V, Petrovic D (2016) Atrophoderma of Pasini and Pierini associated with extramedullary plasmacytoma. Clin Exp Dermatol ;41","DOI":"10.1111\/ced.12906"},{"key":"3357_CR23","unstructured":"Kope\u0107-Medrek M, Kotulska A, Zyci\u0144ska-Debska E, Widuchowska M, Kucharz EJ (2010) Exacerbated course of atrophoderma of Pasini and Pierini in patient with papillary cancer of the thyroid gland. Wiad Lek ;63"},{"key":"3357_CR24","doi-asserted-by":"crossref","unstructured":"Chang CM, Landgren O, Koshiol J, Bj\u00f6rkholm M, L\u00f6ve TJ, Kristinsson SY (2012) Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden. Int J Cancer ;131","DOI":"10.1002\/ijc.27483"},{"key":"3357_CR25","doi-asserted-by":"crossref","unstructured":"Gaur G, Sawant JY, Chavan AS et al (2021) Effect of invasion of borrelia burgdorferi in normal and neoplastic mammary epithelial cells. Antibiotics ;10","DOI":"10.3390\/antibiotics10111295"},{"key":"3357_CR26","doi-asserted-by":"crossref","unstructured":"Buechner SA, Rufli T (1994) Atrophoderma of Pasini and Pierini: clinical and histopathologic findings and antibodies to Borrelia burgdorferi in thirty-four patients. J Am Acad Dermatol ;30","DOI":"10.1016\/S0190-9622(94)70053-2"},{"key":"3357_CR27","doi-asserted-by":"crossref","unstructured":"Lee Y, Oh Y, Ahn SY, Park HY, Choi EH (2011) A case of atrophoderma of Pasini and Pierini associated with Borrelia burgdorferi infection successfully treated with oral doxycycline. Ann Dermatol ;23","DOI":"10.5021\/ad.2011.23.3.352"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03357-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03357-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03357-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:11:02Z","timestamp":1729699862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03357-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3357"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03357-7","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"20 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted with approval from the institutional review board (Approval Number [2021\u2009\u2212\u20091401]). Since the study didn\u2019t include information or images that could identify patients, informed consent wasn\u2019t required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors met the criteria for authorship.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"611"}}